Shire Files Vyvanse Drug for the Treatment of ADHD in Adults
Posted on: Tuesday, 3 July 2007, 21:17 CDT
Shire has submitted a supplemental new drug application to the FDA for its Vyvanse drug for the treatment of ADHD in adults. The application is subject to a 10-month FDA review period.
Vyvanse is a prodrug stimulant that is therapeutically inactive until metabolized in the body and active d-amphetamine is released. Shire says the drug is different from other oral long acting stimulants of amphetamine and methylphenidate that rely on delivery systems which may be affected by pH and GI transit time.
The company plans to announce full results from its phase III clinical trial for the treatment of ADHD in adults at a major scientific conference in Q4 2007.
The FDA approved Vyvanse on February 23, 2007, to treat symptoms of ADHD in children aged six to 12.
Source: Datamonitor
Related Articles
- Report Finds Rising Abuse Of ADHD Drugs
- FDA Orders ADHD Drug Guidelines
- Shire Seeks Approval for Long-Acting ADHD Drug
- FDA Panel: ADHD Drugs for Kids Need Hallucination Warning
- FDA Sets Date for Decision on Shire ADHD Drug
- FDA Advisors Recommend Strong Warnings on ADHD Drugs
- FDA Approves Pfizer Drug Treating Stomach, Kidney Cancer
- Psychiatric Side Effects of ADHD Drugs Probed
- FDA Probing ADHD Drugs for Side Effects
- ADHD Drug Prescriptions Vary by ZIP Code
 |
 |
User Comments (0)
RSS Feeds